In 2008, after extensive negotiations, Amsterdam Molecular Therapeutics (AMT, Amsterdam, The Netherlands) finally obtained a license from Amgen to advance GDNF gene therapy for PD [216]. The gene discussed is GDNF; the disease is Parkinson disease.